Ipsen S.A. (IPN.PA)

110,80 +1,10 (+1,00 %) À la clôture : 05:35PM CEST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 5 325

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. David Loew	MD, CEO & Director	2,11M	S.O.	1967
Mr. Aymeric Le Chatelier	Executive VP & CFO	731,25k	S.O.	1969
Dr. Aidan Murphy Ph.D.	Executive VP and Head of Technical Operations	S.O.	S.O.	1966
Mr. Craig Marks	Vice-President of Investor Relations	S.O.	S.O.	S.O.
Mr. Francois Garnier	Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer	S.O.	S.O.	1962
Mr. Regis Mulot	Executive VP & Chief Human Resources Officer	S.O.	S.O.	1966
Ms. Dominique Bery	Head of Nordics & Baltics	S.O.	S.O.	1971
Mr. Bartosz Bednarz D.D.S.	Executive VP and Head of Global Product & Portfolio Strategy	S.O.	S.O.	S.O.
Mr. Philippe Lopes-Fernandes CBO	Executive VP & Chief Business Officer	S.O.	S.O.	S.O.
Dr. James Levine M.D., Ph.D.	President of Fondation Ipsen	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Ipsen S.A. en date du 1 septembre 2024 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 7; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.